PharmaCielo Enters U.K. Market with 500kg Initial Shipment to Established Manufacturer and Distributor - Reaches 2021 Agreement

Published: November 19, 2020

PharmaCielo Enters U.K. Market with 500kg Initial Shipment to Established Manufacturer and Distributor - Reaches 2021 Agreement

PharmaCielo Ltd., the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., is pleased to announce that it has delivered its first commercial shipment of medicinal grade CBD isolate (the “Initial Shipment”) to a well-established, bulk distributor and white label manufacturer based in the U.K., with sales and distribution operations in the U.K., and the E.U. (the “Customer”).

In addition, the Company has reached an interim sales agreement with the Customer, lasting until the end of Q1-2021, at which point PharmaCielo expects to have submitted a Novel Foods authorization application for its range of CBD extracts. The interim, renewable agreement enables continued shipments for the remainder of 2020 and calls for the shipment of up to 1,000 kg of CBD Isolate and Broad-Spectrum CBD based on the Customer’s specifications, during Q1-2021. With submission of the Novel Foods authorization application prior to March 31, the Company expects to be in a position to subsequently expand both volume and exported consumable product types during fiscal 2021 in accordance with regulatory requirements.

“As consumer demand for health and wellness products containing cannabinoids continues to expand, PharmaCielo is well-positioned to deliver a portfolio of medicinal-grade extracts at scale to serve the needs of global CBD-market facing providers,” said David Attard, CEO of PharmaCielo Ltd. “Having focused to date on building a world-class infrastructure in Colombia as well as developing a robust product portfolio, we are ideally positioned to become the supplier of choice for large volume B2B sales globally. 2021 will be a very exciting year for the Company as we significantly expand global export volumes, and the addition of the Customer’s relationships throughout international markets long-term, including the U.K. and E.U., support this focus.”

Distribution of CBD products by the Company under its interim sales agreement with the Customer is subject to the approval of the TSX Venture Exchange.

Novel Foods Certification

Novel Foods Certification – obtained from the U.K. Food Service Agency – confirms that consumable CBD products, including isolates, meet strict quality and production process standards in accordance with U.K. and E.U. regulatory requirements regarding consumer protection.  The Customer is currently supporting PharmaCielo’s efforts to attain this certification.

PharmaCielo Ltd. is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing centre located in Rionegro, Colombia.

Recent News

View All News Items

Latest Article

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

At any step in the cannabis supply chain, your labeling system should allow for full control and traceability, from seed to sale. Implementing lean principles and labeling best practices across the cannabis supply chain can help you streamline your seed-to-sale labeling process and help you gain control.

Click below to read the full blog and learn how to reduce waste, cut costs, and gain efficiency with cannabis labeling: https://bit.ly/2KwZ5IQ

Read Article